Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
In addition to mutations in genes, aberrant enhancer element activity at non-coding regions of the genome is a key driver of tumorigenesis. Here, we perform epigenomic enhancer profiling of a cohort of more than forty genetically diverse human colorectal cancer (CRC) specimens. Using normal colonic crypt epithelium as a comparator, we identify enhancers with recurrently gained or lost activity across CRC specimens. Of the enhancers highly recurrently activated in CRC, most are constituents of super enhancers, are occupied by AP-1 and cohesin complex members, and originate from primed chromatin. Many activate known oncogenes, and CRC growth can be mitigated through pharmacologic inhibition or genome editing of these loci. Nearly half of all GWAS CRC risk loci co-localize to recurrently activated enhancers. These findings indicate that the CRC epigenome is defined by highly recurrent epigenetic alterations at enhancers which activate a common, aberrant transcriptional programme critical for CRC growth and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“We therefore used the BRD4 inhibitor, JQ1 (refs 44,46), as a tool to assess the functional role of the gene set demarcated by recurrent gained VELs.”
Self-citationSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Heintzman, N. D., Stuart, R. K., Hon, G., Fu, Y., Ching, C. W., Hawkins, R. D., Barrera, L. O., Van Calcar, S., Qu, C., Ching, K. A., et al. (2007) · Nature Genetics · doi:10.1038/ng1966 · Cited by 3,398 · cited 1×
“HCT116 cells are co-transfected with (1) enhancer-specific gRNA expression plasmids, (2) a linearizing gRNA expression plasmid, (3) a Cas9 expression plasmid, (4) a donor plasmid containing PGK-driven puromycin resistance gene (PuroR) flanked by the linearizing gRNA target sites and (5) a donor plasmid containing PGK-…”
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 1×
“HCT116 cells are co-transfected with (1) enhancer-specific gRNA expression plasmids, (2) a linearizing gRNA expression plasmid, (3) a Cas9 expression plasmid, (4) a donor plasmid containing PGK-driven puromycin resistance gene (PuroR) flanked by the linearizing gRNA target sites and (5) a donor plasmid containing PGK-…”
Self-citationThe NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707 · cited 1×
“We next sought genetic evidence that recurrent VELs are relevant to CRC by intersecting various categories of VELs and enhancers with 75 loci associated with genetic predisposition to CRC through GWAS (Supplementary Data 5) 37 .”
Histone modifications at human enhancers reflect global cell-type-specific gene expression
Heintzman, N. D., Hon, G. C., Hawkins, R. D., Kheradpour, P., Stark, A., Harp, L. F., Ye, Z., Lee, L. K., Stuart, R. K., Ching, C. W., et al. (2009) · Nature · doi:10.1038/nature07829 · Cited by 2,533 · cited 1×
“HCT116 cells are co-transfected with (1) enhancer-specific gRNA expression plasmids, (2) a linearizing gRNA expression plasmid, (3) a Cas9 expression plasmid, (4) a donor plasmid containing PGK-driven puromycin resistance gene (PuroR) flanked by the linearizing gRNA target sites and (5) a donor plasmid containing PGK-…”
Cited by
The AP-1 transcriptional complex: Local switch or remote command?
Bejjani, F., Evanno, E., Zibara, K., Piechaczyk, M., & Jariel-Encontre, I. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.003 · Cited by 352
Miguel-Escalada, I., Bonàs-Guarch, S., Cebola, I., Ponsa-Cobas, J., Mendieta-Esteban, J., Atla, G., Javierre, B. M., Rolando, D. M. Y., Farabella, I., Morgan, C. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0457-0 · Cited by 279
Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs
Flavahan, W. A., Drier, Y., Johnstone, S. E., Hemming, M. L., Tarjan, D. R., Hegazi, E., Shareef, S. J., Javed, N. M., Raut, C. P., Eschle, B. K., et al. (2019) · Nature · doi:10.1038/s41586-019-1668-3 · Cited by 255
Chromatin accessibility profiling methods
Minnoye, L., Marinov, G. K., Krausgruber, T., Pan, L., Marand, A. P., Secchia, S., Greenleaf, W. J., Furlong, E. E. M., Zhao, K., Schmitz, R. J., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-020-00008-9 · Cited by 206
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence
Morrow, J. J., Bayles, I., Funnell, A. P. W., Miller, T. E., Saiakhova, A., Lizardo, M. M., Bartels, C. F., Kapteijn, M. Y., Hung, S., Mendoza, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4475 · Cited by 161
Self-citation
Metadata
- Authors
- Cohen, A. J., Saiakhova, A., Corradin, O., Luppino, J. M., Lovrenert, K., Bartels, C. F., Morrow, J. J., Mack, S. C., Dhillon, G., Beard, L., Myeroff, L., Kalady, M. F., Willis, J., Bradner, J. E., Keri, R. A., Berger, N. A., Pruett-Miller, S. M., Markowitz, S. D., & Scacheri, P. C.
- Venue
- Nature Communications
- Published
- 2017-02-07
- Volume
- 8
- Issue
- 1
- Pages
- 14400-14400
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W2587617032
- Cited by
- 119
- References
- 22
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. https://app.cochat.ai/papers/10.1038/ncomms14400
- The paper
- Cohen, A. J., Saiakhova, A., Corradin, O., Luppino, J. M., Lovrenert, K., Bartels, C. F., Morrow, J. J., Mack, S. C., Dhillon, G., Beard, L., Myeroff, L., Kalady, M. F., Willis, J., Bradner, J. E., Keri, R. A., Berger, N. A., Pruett-Miller, S. M., Markowitz, S. D., & Scacheri, P. C. (2017). Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nature Communications. https://doi.org/10.1038/ncomms14400
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.